Glycoprotein IIb-IIIa inhibitors – Do we still need them?

Subban, Vijayakumar; Chandra, K. Sarat

doi:10.1016/j.ihj.2013.04.032

Cited by 5 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, studies have shown that aggressive inhibition of platelet function by platelet αIIbβ3 inhibitors is associated with increased risk of bleeding and only modestly improved mortality. [47] Despite the effectiveness of current antiplatelet therapies, the irreversibility and continued use of these agents is associated with severe bleeding complications. [48] Therefore, an adequate level of suppression of platelet function is critical to maintaining the balance between hemostasis and pathologic thrombosis to prevent adverse events.…”

Section: Anti-platelet Therapy In Cardiovascular Diseasementioning

confidence: 99%

Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids

Adili

Hawley

Holinstat

2018

Prostaglandins & Other Lipid Mediators

View full text Add to dashboard Cite

Thrombosis is the most common underlying pathology responsible for morbidity and mortality in cardiovascular disease (CVD). Platelet adhesion, activation, and aggregation play central roles in hemostasis; however, the same process may also cause thrombosis and vessel occlusion at the site of ruptured atherosclerotic lesions leading to heart attack and stroke. ω-3 and ω-6 polyunsaturated fatty acids (PUFAs) are an essential component of the platelet phospholipid membrane and play a major role in many aspects of platelet function. Dietary supplementation of ω-3 and ω-6 PUFAs has long been used to slow the progression of CVD and to prevent acute cardiovascular events. Despite this, the role of ω-3 and ω-6 PUFAs and their oxylipin metabolites in platelet function remains controversial due to the lack in our understanding of the mechanistic regulation controlling platelet reactivity in vitro and substantial evidence for PUFA regulation of thrombotic events in vivo. In this review, we will outline the role of platelet physiology in hemostasis and the effect of ω-3 and ω-6 PUFAs on platelet function, with special emphasis on in vivo effects on hemostasis and thrombosis due to the role of PUFAs and their bioactive lipids in circulation. Further, recent mechanistic insights and evidence for cardio-protective effects of PUFAs and their bioactive lipids will be discussed.

show abstract

Section: Anti-platelet Therapy In Cardiovascular Diseasementioning

confidence: 99%

Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids

Adili

Hawley

Holinstat

2018

Prostaglandins & Other Lipid Mediators

View full text Add to dashboard Cite

show abstract

“…The platelet integrin complex glycoprotein (GP) IIb/IIIa represents the final common pathway of platelet activation. 54,55 This molecule mediates platelet adhesion via binding to fibrinogen thereby forming bridges between platelets. A haemostatic platelet plug subsequently develops, which increases in size as further platelet activation is propagated.…”

Section: Glycoprotein Iib/iiia Inhibitors In Acute Coronary Syndromementioning

confidence: 99%

“…Of the drugs in this class, abciximab (a monoclonal antibody fragment), tirofiban (a small, non-peptide molecule) and eptifibatide (a cyclic heptapeptide derived from rattlesnake venom) are used in clinical practice. 55,56 Abciximab additionally binds to integrin receptors on leucocytes and endothelial cells, thus reducing the adhesion of platelets to these cells. 56 GP IIb/IIIa inhibitors have played varying roles as antiplatelet agents over the past 20 years.…”

Section: Glycoprotein Iib/iiia Inhibitors In Acute Coronary Syndromementioning

confidence: 99%

“…56 GP IIb/IIIa inhibitors have played varying roles as antiplatelet agents over the past 20 years. 55 Data from several large-scale meta-analyses looking at GP IIb/IIIa inhibitor clinical trials in the medical management of non-ST-elevation ACS indicate a significant reduction in further MI and overall mortality in patients treated with these agents, 57,58 and although they were formerly used as key therapies in the management of acute MI for several years, GP IIb/IIIa inhibitors have been gradually phased out in favour of the P2Y 12 inhibitors.…”

Section: Glycoprotein Iib/iiia Inhibitors In Acute Coronary Syndromementioning

confidence: 99%

See 1 more Smart Citation

Antiplatelet Therapy in Acute Coronary Syndrome

Layne

Ferro

2017

European Cardiology Review

View full text Add to dashboard Cite

Antiplatelet agents have for decades been used to improve outcomes in patients with acute coronary syndromes and have become increasingly valued, not only for their antithrombotic properties but also for their anti-inflammatory effects. The drug class continues to evolve as novel agents with increasingly efficacious antiplatelet actions are identified. This review will discuss antiplatelet agents, including aspirin, the P2Y12 receptor antagonists and the glycoprotein IIb/IIIa inhibitors, that are currently used to treat patients with unstable angina and myocardial infarction, focusing on their pharmacological properties and the clinical evidence supporting their use.

show abstract

Periprocedural Anticoagulation and Antiplatelet Medications Management for Interventional Radiology Procedures

Abbas

Harb

et al. 2021

Curr Radiol Rep

View full text Add to dashboard Cite

Glycoprotein IIb-IIIa inhibitors – Do we still need them?

Cited by 5 publications

References 35 publications

Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids

Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids

Antiplatelet Therapy in Acute Coronary Syndrome

Periprocedural Anticoagulation and Antiplatelet Medications Management for Interventional Radiology Procedures

Contact Info

Product

Resources

About